The development of MDM2–p53 disruptors for cancer therapy has been a major focus in the field for decades, and currently, several such inhibitors including MI-77301 (SAR405838), MK-8242 compound (SCH-900242), and AMG232 are under clinical trials (15). The gene discussed is TP53; the disease is cancer.